Clinical trials: HCM
Hypertrophic Cardiomyopathy
Risk Stratification Using PET in HCM
The overall rationale is to reduce the risk of sudden cardiac death in individuals with hypertrophic cardiomyopathy (HCM). The novel approach of this study is to correlate Positron Emission Tomography (PET) findings to…
- Trial name
- HCM-PET (NCT03278457)
- Testing
- Positron Emission Tomography
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Region Gävleborg
Hypertrophic Cardiomyopathy
Pirfenidone to Treat Hypertrophic Cardiomyopathy
This study will examine the effectiveness of the drug pirfenidone (Deskar) in improving heart function in patients with hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT00011076
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
- Trial name
- CEDAR-HCM (NCT06412666)
- Testing
- Aficamten
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 65 people
- Sponsor
- Cytokinetics
Hypertrophic Cardiomyopathy (HCM)
HCMR Re-Imaging Study
This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT07054073
- Testing
- None - observational study
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 314 people
- Sponsor
- Christopher Kramer
Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy Federated Learning Implementation Platform
HCM FLIP study is a two-phase protocol focusing on the detection of Hypertrophic Cardiomyopathy using Electrocardiograms and Echocardiograms through Federated Learning.
- Trial name
- HCM FLIP (NCT06461468)
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- American Heart Association
Cardiomyopathies
Analysis of Cardiac Biomarkers, ECG and CPET Results in Children With Cardiomyopathies
The aim of the study is to analyze cardiac biomarkers, electrocardiograms and cardio-pulmonary exercise test (CPET) results in children with cardiomyopathies.
- Trial name
- NCT04316923
- Testing
- ECG, 24-hour ECG monitoring, Cardio-pulmonary exercise test (CPET)
- Where
- Poland
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Katarzyna Łuczak-Woźniak
Hypertrophic Cardiomyopathy
Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
The primary aim of this study will be to assess whether Biventricular pacing improves exercise capacity, and Quality of Life in patients with symptomatic drug resistant Non-Obstructive Hypertrophic Cardiomyopathy, using a…
- Trial name
- NCT00698074
- Testing
- Cardiac Resynchronisation Therapy
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University Hospital Birmingham
Hypertrophic Cardiomyopathy
Machine Learning Approach Based on Echocardiographic Data to Improve Prediction of Cardiovascular Events in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is a pathology with a highly variable course, ranging from patients who are asymptomatic throughout their lives to those who experience sudden death and/or terminal heart failure.
- Trial name
- 2022PI172 (NCT06256913)
- Where
- 2 sites in France
- Volunteers
- 870 people
- Sponsor
- Pr. Nicolas GIRERD
Syndromic and Metabolic Cardiomyopathy, Cardiomyopathies
SMCs With LVH Compared to HCM
The goal of this cohort study is to investigate the clinical characteristics of SMCs and to explore the difference in cardiovascular outcomes in comparison to age-, sex-, and admission year-matched HCM patients.
- Trial name
- NCT07006974
- Testing
- SMCs
- Where
- China
- Volunteers
- 165 people
- Sponsor
- China National Center for Cardiovascular Diseases
Hypertrophic Cardiomyopathy
Non-Invasive Radiation Ablation in Patients With Hypertrophic CardioMyopathy: NIRA-HOCM
Hypertrophic cardiomyopathy (HCM) is a common disease of the heart which causes thickening of the heart muscle. HCM primarily affects the muscle of the main pumping chamber of the heart (the left ventricle) and particularly the…
- Trial name
- NIRA-HOCM (NCT04153162)
- Testing
- Stereotactic body radiation therapy
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Barts & The London NHS Trust
Hypercalcemia of Malignancy
A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM
The purpose of this study is to determine the potential of JMT103 to treat hypercalcemia of malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates.
- Trial name
- NCT04198480
- Testing
- JMT103
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Shanghai JMT-Bio Inc.
Hypertrophic Cardiomyopathy
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and…
- Trial name
- VANISH (NCT01912534)
- Testing
- Valsartan
- Where
- 15 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- Carelon Research
Hypertrophic Cardiomyopathy, Long QT Syndrome
Exercise in Genetic Cardiovascular Conditions
The goal is to determine how lifestyle and exercise impact the well-being of individuals with hypertrophic cardiomyopathy (HCM) and long QT syndrome (LQTS).
- Trial name
- LIVE-HCM/LQT (NCT02549664)
- Where
- 36 sites in United States, Australia and 3 more
- Volunteers
- 4,299 people
- Sponsor
- Yale University
Cardiomyopathy, Hypertrophic
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT06253221
- Testing
- Mavacamten
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 44 people
- Sponsor
- Bristol-Myers Squibb
HOCM, Hypertrophic Obstructive Cardiomyopathy
CRyo-Ablation to Treat Patients With HOCM.
The purpose of the study is to perform endocardial catheter CRyo-Ablation to relieve the LVOT obstruction in patients with Hypertrophic Obstructive Cardiomyopathy.
- Trial name
- CRASH (NCT01875016)
- Testing
- CRyo-Ablation to Treat HOCM.
- Volunteers
- 15 people
- Sponsor
- Shaare Zedek Medical Center
Coronary Cicrovascular Dysfunction, Hypertrophic Cardiomyopathy Patients
Prognostic Significance of CMD Assessed by IMR in HCM Patients
The index of microcirculatory resistance (IMR) serves as an indicator of coronary microvascular dysfunction (CMD) with significant prognostic value in various clinical conditions.
- Trial name
- caIMR-HCM (NCT06190704)
- Testing
- caIMR
- Volunteers
- 191 people
- Sponsor
- Ya-Wei Xu
Hypertrophic Cardiomyopathy
Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is a relatively common inherited heart muscle disease. Many patients experience symptoms of breathlessness, fatigue and chest pain.
- Trial name
- METAL-HCM (NCT00500552)
- Where
- 3 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- University Hospital Birmingham
Fabry Disease, Fabry Disease, Cardiac Variant
Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score
This study aims to evaluate the prevalence of Fabry Disease (FD) among a cohort of high risk patients with left ventricular hypertrophy (LVH) presenting at the University Hospital Würzburg over the last 20 years.
- Conditions
- Fabry Disease, Fabry Disease, Cardiac Variant, Lysosomal Storage Diseases, HCM - Hypertrophic Cardiomyopathy
- Trial name
- FAPREV-HCM (NCT04943991)
- Testing
- blood sampling (alpha-Galactosidase & LysoGb3)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Wuerzburg University Hospital
Cardiomyopathy, Hypertrophic
A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
The purpose of this study is to characterize the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MYK-224 in participants with obstructive Hypertrophic Cardiomyopathy (oHCM)
- Trial name
- MERCUTIO (NCT05556343)
- Testing
- MYK-224
- Where
- 25 sites in United States, Italy and 2 more
- Volunteers
- 18 people
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathy
Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis
Hypertrophic cardiomyopathy (HCM) is hallmarked by the presence of left ventricular hypertrophy (LVH) and may present various symptoms including arrhythmia and heart failure.
- Trial name
- NCT06381778
- Where
- Taiwan
- Volunteers
- 2,600 people
- Sponsor
- Far Eastern Memorial Hospital